Article Text

AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity
  1. F. Iannone1,
  2. G. Ferraccioli2,
  3. C. Ferri3,
  4. M. Galeazzi4,
  5. R. Gerli5,
  6. R. Giacomelli6,
  7. W. Grassi7,
  8. R. Gorla8,
  9. M. Govoni9,
  10. A. Marchesoni10,
  11. L. Punzi11,
  12. P. Sarzi-Puttini12,
  13. G. Triolo13,
  14. G. Lapadula1
  1. 1DIM, Rheumatology Unit-University of Bari, Bari
  2. 2Rheumatology Unit, University Cattolica of Sacre Hearth, Roma
  3. 3Rheumatology Unit, University of Modena e Reggio Emilia, Modena
  4. 4Rheumatology Unit, University of Siena, Siena
  5. 5Rheumatology Unit, University of Perugia, Perugia
  6. 6Rheumatology Unit, University of L’Aquila, L’Aquila
  7. 7Università Politecnica delle Marche, Jesi
  8. 8Rheumatology Unit, University of Brescia, Brescia
  9. 9Rheumatology Unit, University of Ferrara, Ferrara
  10. 10Rheumatology Unit, G. Pini, Milano
  11. 11Rheumatology Unit, University of Padova, Padova
  12. 12Rheumatology Unit, L Sacco, Milano
  13. 13Rheumatology Unit, University of Palermo, Palermo, Italy


Background Rheumatoid arthritis (RA) is conventionally defined as moderate when the disease activity score assessed in 28 joints (DAS28) is ≥3.2, and high disease with DAS28 >5.1

Objectives Aim of this analysis was to evaluate the rate of remission and LDA (low disease activity), in RA patients starting etanercept therapy with moderate disease activity in the real world settings

Methods The clinical records were retrospectively analysed from the Italian nationwide registry, called GISEA (Gruppo Italiano Studio Early Arthritis). RA patients with moderate (Mod-RA) and high (H-RA) disease activity (DAS28 >3.2) with incomplete response to conventional DMARDs and beginning a treatment with etanercept 50 mg/week subcutaneously (or 25 mg twice/week) over 10 years (2001-2010) were considered and compared. Clinical remission (DAS28 <2.6), LDA (DAS28 <3.2), HAQ, EULAR clinical response were assessed at 6 and 12 months of therapy, and etanercept survival rate at 1 and 4 years

Results 963 patients with moderate to severe RA were selected. Out of 963, 320 had Mod-RA and 633 H-RA. At 1 year, the rate of patients achieving DAS28 remission were significantly higher in Mod-RA (47.9%) than in H-RA (24.5%, p<0.001), and patients achieving LDA was significantly higher in Mod-RA (65.9%) than in H-RA (36.7%, p<0.001). “Good” EULAR response was significantly higher in Mod-RA (58.9%) than in H-RA group (36.7%) (p<0.01). Surprisingly, the retention rate of etanercept was significantly higher in H-RA patients (84.5%) than in Mod-RA patients (75.4%), both at 1 year (p<0.01) and at 4 years, 58.4% and 48.8%, respectively (p<0.01). Also the HAQ response was intriguing. In H-RA patients, mean HAQ score was 1.6 at baseline and 0.83 at 12 months (mean difference 0.77), while in Mod-RA patients, mean HAQ score was 1.01 at baseline and fell down at 0.55 after 6 months (mean difference 0.46, p=0.0001).Apparently patients starting with high disease activity have more room for improvement in HAQ, but the patients starting with moderate RA reach better absolute levels.Univariate and multivariate logistic regression analysis did not detect any predictor of response differentiating patients with H-RA from those with Mod-RA

Conclusions Consistently with previous reports, this preliminary data have provided evidence that in standard care setting Mod-RA patients had a high likelihood to achieve a DAS28 driven clinical remission as well as a condition of LDA when treated with etanercept

Disclosure. This analysis was supported by Pfizer Inc.

Disclosure of Interest F. Iannone Grant/Research support from: Pfizer Inc., G. Ferraccioli: None Declared, C. Ferri: None Declared, M. Galeazzi: None Declared, R. Gerli: None Declared, R. Giacomelli: None Declared, W. Grassi: None Declared, R. Gorla: None Declared, M. Govoni: None Declared, A. Marchesoni: None Declared, L. Punzi: None Declared, P. Sarzi-Puttini: None Declared, G. Triolo: None Declared, G. Lapadula: None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.